2012
Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America
Silverberg MJ, Lau B, Justice AC, Engels E, Gill MJ, Goedert JJ, Kirk GD, D’Souza G, Bosch RJ, Brooks JT, Napravnik S, Hessol NA, Jacobson LP, Kitahata MM, Klein MB, Moore RD, Rodriguez B, Rourke SB, Saag MS, Sterling TR, Gebo KA, Press N, Martin JN, Dubrow R, Research and Design of IeDEA T. Risk of Anal Cancer in HIV-Infected and HIV-Uninfected Individuals in North America. Clinical Infectious Diseases 2012, 54: 1026-1034. PMID: 22291097, PMCID: PMC3297645, DOI: 10.1093/cid/cir1012.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusAnal cancer incidence ratesAnal cancer ratesCancer incidence ratesAnal cancerIncidence rateCancer ratesRate ratioMultivariable Poisson regression modelsAntiretroviral therapy eraPoisson regression modelsHIV-InfectedTherapy eraUniversal prevention effortsImmunodeficiency virusCommon cancerCalendar trendsMSMPrevention effortsCancerWomenMenRegression modelsRiskIndividuals
2005
Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America
Girardi E, Sabin CA, d'Arminio Monforte A, Hogg B, Phillips AN, Gill MJ, Dabis F, Reiss P, Kirk O, Bernasconi E, Grabar S, Justice A, Staszewski S, Fätkenheuer G, Sterne JA. Incidence of Tuberculosis among HIV-Infected Patients Receiving Highly Active Antiretroviral Therapy in Europe and North America. Clinical Infectious Diseases 2005, 41: 1772-1782. PMID: 16288403, DOI: 10.1086/498315.Peer-Reviewed Original ResearchConceptsIncidence of tuberculosisMonths of HAARTMultivariable analysisMultivariable Poisson regression modelsInitiation of HAARTLevel of immunodeficiencyLower baseline CD4Active antiretroviral therapyHIV RNA levelsRisk of tuberculosisInjection drug usersMode of transmissionPoisson regression modelsBaseline CD4HAART initiationHigher CD4Antiretroviral therapyTB epidemicIncidence rateCopies/HAARTDrug usersPatientsTuberculosisCD4